Santen Pharmaceutical Company Description
Santen Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and marketing of pharmaceuticals and medical devices in Japan and internationally.
Its product portfolio includes tafluprost/timolol maleate, a prostaglandin F2α derivative and a beta-adrenergic receptor blocker; and netarsudil mesilate and latanoprost, a prostaglandin F2α derivative which is marketing approval phase for the treatment of glaucoma and ocular hypertension.
The company also offers sepetaprost, a prostaglandin analogue eye drop drug that is in phase 3 of clinical trials; and latanoprost, an ophthalmic emulsion of a prostaglandin F2α derivative which is filed for marketing approval for the treatment of glaucoma and ocular hypertension.
In addition, it provides cyclosporin, an ophthalmic emulsion for the treatment of vernal keratoconjunctivitis; and diquafosol sodium for dry eye treatment.
Further, the company develops olodaterol hydrochloride, a β2 receptor agonist that is in phase 1/2a for the treatment of A dry eye treatment dry eye; sirolimus, an ophthalmic suspension which is in phase 2a for the treatment of 4 Fuchs endothelial corneal dystrophy and meibomian gland dysfunction; epinastine hydrochloride, a histamine H₁ receptor antagonist filed for marketing approval for the treatment of allergic conjunctivitis; atropine sulfate, a non-selective muscarinic antagonist that is in phase 2/3 clinical trials for myopia treatment; and AFDX0250BS, an selective muscarinic M2 antagonist which is in phase 2a for the treatment of myopia.
Additionally, it offers ursodeoxycholic acid that is in phase 2a of clinical trial for the treatment of presbyopia; and oxymetazoline hydrochloride, a direct-acting alpha adrenergic receptor agonist which is in phase 3 for treatment of ptosis.
The company was founded in 1890 and is headquartered in Osaka, Japan.
| Country | Japan |
| Founded | 1890 |
| Industry | Drug Manufacturers - General |
| Sector | Healthcare |
| Employees | 3,744 |
| CEO | Takeshi Ito |
Contact Details
Address: Grand Front Osaka Tower A Osaka, 530-8552 Japan | |
| Phone | 81 6 7664 8621 |
| Website | santen.com |
Stock Details
| Ticker Symbol | SNPHF |
| Exchange | OTCMKTS |
| Stock Type | Common Stock |
| Fiscal Year | April - March |
| Reporting Currency | JPY |
| ISIN Number | JP3336000009 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Takeshi Ito | President, Chief Executive Officer and Representative Director |
| Kazuo Koshiji | Chief Financial Officer and Corporate Officer |
| Rie Nakajima | Chief Operating Officer, Corporate Officer and Director |
| Kaori Itagaki | General Manager of Investor Relations Group |
| Mika Masunari | General Counsel and Chief Compliance Officer |
| Nobuko Kato | Chief Communications Officer |
| Shinichi Teramachi | Corporate Officer, Head of Sales and Head of Japan Sales and Marketing |
| Kenji Morishima | Corporate Officer and Head of China Product Development Department |
| Takahiro Morita | Global Head of Core Principle and Sustainability and Corporate Officer |
| Frank Binder | Corporate Officer and Head of Supply Chain Division |